Fulcrum Capital LLC Increases Stock Position in Edwards Lifesciences Corporation $EW

Fulcrum Capital LLC lifted its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 3.8% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 131,109 shares of the medical research company’s stock after buying an additional 4,842 shares during the period. Edwards Lifesciences makes up approximately 2.2% of Fulcrum Capital LLC’s holdings, making the stock its 16th largest position. Fulcrum Capital LLC’s holdings in Edwards Lifesciences were worth $10,254,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in EW. Jennison Associates LLC grew its stake in shares of Edwards Lifesciences by 34.3% in the 1st quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company’s stock valued at $731,036,000 after purchasing an additional 2,576,383 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Edwards Lifesciences by 4.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,783,568 shares of the medical research company’s stock valued at $491,673,000 after purchasing an additional 264,311 shares during the last quarter. Nuveen LLC purchased a new position in shares of Edwards Lifesciences in the 1st quarter valued at approximately $330,881,000. Invesco Ltd. grew its stake in shares of Edwards Lifesciences by 2.6% in the 1st quarter. Invesco Ltd. now owns 4,287,712 shares of the medical research company’s stock valued at $310,773,000 after purchasing an additional 107,241 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Edwards Lifesciences by 5.3% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 3,961,643 shares of the medical research company’s stock valued at $287,140,000 after purchasing an additional 198,882 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Daiwa America upgraded Edwards Lifesciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 29th. The Goldman Sachs Group reiterated a “buy” rating on shares of Edwards Lifesciences in a research note on Friday, July 25th. Morgan Stanley boosted their price target on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 15th. Truist Financial boosted their price target on shares of Edwards Lifesciences from $81.00 to $82.00 and gave the stock a “hold” rating in a research note on Friday, July 25th. Finally, Evercore ISI set a $88.00 price target on shares of Edwards Lifesciences and gave the stock an “outperform” rating in a research note on Tuesday. Three research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and an average price target of $87.06.

Insider Activity

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 4,114 shares of the company’s stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the transaction, the vice president directly owned 22,002 shares in the company, valued at approximately $1,748,278.92. This represents a 15.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Larry L. Wood sold 8,950 shares of the company’s stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the transaction, the insider owned 206,900 shares in the company, valued at $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Trading Down 1.6%

Shares of EW opened at $74.02 on Friday. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. The firm’s 50-day moving average is $78.09 and its two-hundred day moving average is $76.10. Edwards Lifesciences Corporation has a twelve month low of $64.89 and a twelve month high of $83.00. The firm has a market capitalization of $43.46 billion, a P/E ratio of 10.65, a PEG ratio of 3.61 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same period in the prior year, the business posted $0.70 earnings per share. The firm’s revenue for the quarter was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, research analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.